LEGEND BIOTECH CORP (LEGN)
Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)
Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)
📈 **POSITIVE** • Medium confidence analysis (61%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (74%) **Content type:** Clinical